686 related articles for article (PubMed ID: 17631244)
41. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
42. Genistein inhibits glucocorticoid amplification in adipose tissue by suppression of 11β-hydroxysteroid dehydrogenase type 1.
Tagawa N; Kubota S; Kobayashi Y; Kato I
Steroids; 2015 Jan; 93():77-86. PubMed ID: 25447798
[TBL] [Abstract][Full Text] [Related]
43. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
Arampatzis S; Kadereit B; Schuster D; Balazs Z; Schweizer RA; Frey FJ; Langer T; Odermatt A
J Mol Endocrinol; 2005 Aug; 35(1):89-101. PubMed ID: 16087724
[TBL] [Abstract][Full Text] [Related]
44. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
[TBL] [Abstract][Full Text] [Related]
45. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
[TBL] [Abstract][Full Text] [Related]
46. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
47. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.
Seckl JR; Morton NM; Chapman KE; Walker BR
Recent Prog Horm Res; 2004; 59():359-93. PubMed ID: 14749510
[TBL] [Abstract][Full Text] [Related]
48. Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11beta-hydroxysteroid dehydrogenase 1.
Balázs Z; Nashev LG; Chandsawangbhuwana C; Baker ME; Odermatt A
Mol Cell Endocrinol; 2009 Mar; 301(1-2):117-22. PubMed ID: 19010388
[TBL] [Abstract][Full Text] [Related]
49. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
50. Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Scott JS; Goldberg FW; Turnbull AV
J Med Chem; 2014 Jun; 57(11):4466-86. PubMed ID: 24294985
[TBL] [Abstract][Full Text] [Related]
51. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
[TBL] [Abstract][Full Text] [Related]
52. The role of 11beta-hydroxysteroid dehydrogenases in the brain.
Holmes MC; Seckl JR
Mol Cell Endocrinol; 2006 Mar; 248(1-2):9-14. PubMed ID: 16413106
[TBL] [Abstract][Full Text] [Related]
53. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Odermatt A
Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703
[TBL] [Abstract][Full Text] [Related]
54. A transgenic model of visceral obesity and the metabolic syndrome.
Masuzaki H; Paterson J; Shinyama H; Morton NM; Mullins JJ; Seckl JR; Flier JS
Science; 2001 Dec; 294(5549):2166-70. PubMed ID: 11739957
[TBL] [Abstract][Full Text] [Related]
55. Localization and glucocorticoid regulation of 11beta-hydroxysteroid dehydrogenase type 1 mRNA in the male mouse forebrain.
Pelletier G; Luu-The V; Li S; Bujold G; Labrie F
Neuroscience; 2007 Mar; 145(1):110-5. PubMed ID: 17207581
[TBL] [Abstract][Full Text] [Related]
56. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.
Cooper MS; Stewart PM
J Clin Endocrinol Metab; 2009 Dec; 94(12):4645-54. PubMed ID: 19837912
[TBL] [Abstract][Full Text] [Related]
57. Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes.
Tagawa N; Kubota S; Kato I; Kobayashi Y
J Endocrinol; 2013 Sep; 218(3):311-20. PubMed ID: 23814014
[TBL] [Abstract][Full Text] [Related]
58. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
[TBL] [Abstract][Full Text] [Related]
59. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds.
Blum A; Favia AD; Maser E
Mol Cell Endocrinol; 2009 Mar; 301(1-2):132-6. PubMed ID: 18822345
[TBL] [Abstract][Full Text] [Related]
60. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]